JACC This Week podcast

Monotherapy in HBR Patients: What STOPDAPT-3 Tells Us | JACC Baran

2025-06-24
0:00
31:30
Spola tillbaka 15 sekunder
Spola framåt 15 sekunder

Hosts Mitsuaki Sawano, MD, Kentaro Ejiri, MD, and Nobuhiro Ikemura, MD, welcome Yuki Obayashi, MD, of Leiden University Medical Center, to discuss findings from the STOPDAPT-3 trial. Dr. Obayashi highlights that, among ACS patients—including those with HBR or STEMI—aspirin and clopidogrel monotherapy after 1 month of DAPT resulted in similar rates of ischemic and bleeding events. These results support flexible, patient-centered antiplatelet strategies beyond the acute phase.

Fler avsnitt från "JACC This Week"